Thursday 7 June 2012

Pegylated Liposomal Doxorubicin-Recurrent Ovarian Cancer-Chemotherapy-Phase Iii

Roche study showed that adding Avastin to chemotherapy cut the risk of the disease getting worse in difficult-to-treat recurrent ovarian cancer by half

Roche today announced results from AURELIA, a phase III study that evaluated treatment with Avastin (bevacizumab) in combination with standard chemotherapy (weekly paclitaxel, topotecan or pegylated liposomal doxorubicin) in women with ovarian cancer whose disease had worsened due to resistance to platinum-containing chemotherapy. (Source: Roche Media News) read more..

No comments:

Post a Comment